oncgnostics GmbH
The oncgnostics GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.
oncgnostics GmbH is working according to ISO 13485 standards in research, development, production and management.
Recent Posts
Upcoming Events
-
MEDICA 2022 in Düsseldorf, Germany
14. November - 17. November
Contact
oncgnostics GmbH
Löbstedter Str. 41
07749 Jena
Germany
Phone: +49 (0)3641 5548500
Email: contact[at]oncgnostics.com
Internet: www.oncgnostics.com
German oncgnostics GmbH‘s innovation in the area of cervical cancer diagnostics now also available in China
Press ReleasesGynTect receives approval in China Jena, August 25, 2022 – The cervical cancer screening test GynTect is now available to physicians and patients in China, the world’s most populous country. The product is the first approved methylation test for triage of HPV-positive cases in China. GynTect was developed by oncgnostics GmbH and is already approved […]
PCR test detects cervical precancerous lesions
Blog, Press ReleasesJena, Germany, May 25th 2022 – May 28 marks the 35th International Day of Action for Women’s Health. One “female” disease that should no longer exist due to the availability of modern cancer-screening methods is cervical cancer. One step in the direction of abolishing this form of cancer has been taken by the German life […]
Cancer prevention remains a matter of the heart: Biotech company oncgnostics celebrates 10th anniversary
Press ReleasesThe company oncgnostics GmbH, founded in 2012, already launched its first product in 2015: the diagnostic test for cervical cancer “GynTect”. This is now sold in over ten countries in Europe and Asia. In addition, oncgnostics conducts research in the field of diagnostics for head and neck cancer. The company is growing steadily and has […]
Pilot study: Cancer screening from home is possible
Press ReleasesA large proportion of women who develop cervical cancer in high-income countries such as Germany do not regularly attend screening. This is particularly alarming, as cancer screenings have become much less frequent since the onset of the corona pandemic. A study by Hannover Medical School and the biotechnology company oncgnostics GmbH is testing self-tests as […]
International sales partnership with EUROIMMUN for Distribution of GynTect
Press ReleasesBiotechnology company oncgnostics GmbH is announcing a collaboration with the international diagnostics group EUROIMMUN, a PerkinElmer company. As part of the cooperation, EUROIMMUN will sell the cervical cancer test from oncgnostics GmbH, Gyn-Tect, in the European countries of Portugal, Italy, Turkey and Poland. Also the test is expected to be approved and on sale in […]
On the World Mental Health Day
Press ReleasesAbnormal results in Cervical Cancer Screening may trigger symptoms of post-traumatic stress disorder. Oncgnostics GmbH draws attention to this on the annual World Mental Health Day on 10 October and points out that conspicuous Pap test results and/or positive HPV tests have a negative effect on the psyche of the women concerned. The company, which […]
Cancer screening: Suddenly, it has an effect on family planning
Press ReleasesExperience reports from women who are in family planning, but for whom a conspicuous finding was made during cancer screening, are often characterised by uncertainty and frustration. After a joint appeal with anti-cancer activist Myriam von M., many women told us their stories. Some of them experienced high-risk pregnancies or even miscarriages after a conisation. […]
Sepsis: In which Patients does the Immune System Break Down?
Press ReleasesAs part of a new EU consortium, Oncgnostics GmbH is investigating diagnostic possibilities of immune collapse after sepsis. More than 140 people die every day in Germany of sepsis, commonly known as blood poisoning. Two thirds of them do not die from the out of control inflammatory reactions in the whole body, but rather from […]
Oncgnostics Expands Business Relations in Asia
Press ReleasesApproval for cervical cancer screening test in the Chinese market expected in early 2020 / First contacts in Japan Shanghai/Yokohama/Tokyo/Jena, 1 November 2019 –Our business partner in China, GeneoDx, is about to get approval to commercialise GynTect in the Chinese market. This issue was discussed at a business meeting with representatives from oncgnostics GmbH in […]
Early detection test GynTect® now available for Roche Diagnostics QPCR system
Press ReleasesJena, 20. February, 2019 – The test for early detection of cervical cancer GynTect® may now also be performed on the cobas Z480 analyzer, a widely used quantitative PCR (QPCR) system from Roche Diagnostics. This is now possible through an extension of the GynTect® CE IVD mark (CE mark for in vitro diagnostics). The biotech […]